Eukaryotic Programmed Cell Death Protein 1 (PD1)
CD279; PDCD1; SLEB2; HPD1P
- Product No.EPA751Hu61
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- SourceEukaryotic expression
- Host293F Cell
- Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
- Subcellular LocationMembrane
- Predicted Molecular Mass18.4kDa
- Accurate Molecular Mass36-45kDa(Analysis of differences refer to the manual)
- Residues & TagsPro21~Val170 with N-terminal His Tag
- Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
- Traits Freeze-dried powder
- Purity> 95%
- Isoelectric Point8.7
-
Applications
Positive Control; Immunogen; SDS-PAGE; WB.
If bio-activity of the protein is needed, please check active protein. - DownloadInstruction Manual
- UOM 10µg50µg 200µg 1mg 5mg
- FOB
US$ 240
For more details, please contact local distributors! US$ 600 US$ 1200 US$ 3600 US$ 9000
SEQUENCE
USAGE
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
STORAGE
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- BCA Protein Quantification Kit
- Protein Labeling Customized Service
- Molecular Mass Marker for Protein
- Monoclonal Antibody Customized Service
- Polyclonal Antibody Customized Service
- Protein Activity Test Experiment Service
- Immunoprecipitation (IP) Experiment Service
- Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
- Buffer
- Lentivirus Packaging Experiment Service
- Adenovirus Packaging Experiment Service
- Real Time PCR Experimental Service
- Spike RBD Protein (S-RBD)
- Protein G
- Protein A
Magazine | Citations |
Oncotarget | Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. pubmed:28545019 |
CyberLeninka | Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке : |
АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1‑ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ … | |
International Journal of Molecular Sciences | Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity Pubmed: 30699956 |
PLoS One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … Pubmed: 30807610 |
Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study Pubmed: 32085544 |